Enterprise Value to EBITDA Ratio: Tharimmune, Inc. (THAR)
The development of Tharimmune, Inc. (THAR) relies on antibody trial results for oncology and dermatitis therapies with moderate R&D expenditures. Tharimmune, Inc. (THAR) is creating unique targeted drugs protected by patents and a debt-free balance sheet. The company maintains structural flexibility through production outsourcing. This price action on GURU.Markets illustrates an EV/EBITDA of 0.00, confirming the current market valuation of the business.
Analytical breakdowns for tharimmune.com (THAR)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Tharimmune, Inc.|THAR - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Tharimmune|THAR - Aggregate Debt Obligations|Debts to Book Capitalization Tharimmune Corporation|THAR - Company Long-Term Debts|Company Short-Term Debt Tharimmune|Quick Ratio tharimmune.com
- business earnings and investment ratios data:
THAR - Net Financial Result|Expected Profit Tharimmune, Inc.|THAR - Price to Earnings Ratio|Future Price to Earnings Tharimmune, Inc.|THAR - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Tharimmune Corporation|THAR - Operating profit EBITDA|Earnings per share for the last twelve months Tharimmune|THAR - Earnings per share for the last 12 months|Quarterly EPS earnings growth tharimmune.com|THAR - Earnings per share growth rate in current year|Expected earnings per share growth for next year Tharimmune, Inc.
Summary company analysis:Tharimmune Corp THAR
For Tharimmune, Inc. (THAR), which faces a systematic capital outflow for antibody development, the company's EV/EBITDA ratio over a time series serves as an indicator of the total business value relative to its operational efficiency. This metric combines market capitalization and net debt, allowing an investor to assess the real value of assets compared to the generated earnings before interest, taxes, depreciation, and amortization.
Competitors of Tharimmune, Inc.
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|Enterprise Value to EBITDA Ratio ERAS (Erasca, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio DCTH|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|Business Value to Operating Income Before Depreciation AURA|Candel - EV/EBITDA Multiple|ARAY - EV/EBITDA Multiple|sellaslifesciences.com (SLS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|actuatetherapeutics.com - Business Value to Operating Income Before Depreciation|CTOR (Citius Oncology) - EV/EBITDA Multiple|TuHURA (HURA) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protara (TARA)|Enterprise Value to EBITDA Ratio Fate Pharma FATE|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aadi Bioscience WHWK|TCRX - Enterprise Value to EBITDA Ratio|CSBR: Enterprise Value to EBITDA Ratio|XBIT - EV/EBITDA Multiple|cel-sci.com (CVM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation OSTX|RADX (Radiopharm Theranostics) - EV/EBITDA Multiple|Company Value to EBITDA Artiva ARTV|Enterprise Value to EBITDA Ratio ANL (Adlai Nortye Ltd.)|VERU (Veru Inc) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TPST (Tempest Tx)|Total Company Value to Operating Income Before Depreciation Ratio Xilio Therapeutics Inc (XLO)|RENB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MURA (Mural Oncology plc) - Enterprise Value to Operating Income Before Depreciation|KAPA: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio OnKure Therapeutics|Enterprise Value to EBITDA Ratio GDTC|Curis Corp (CRIS) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio APLM (Apollomics, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ADVB|EV/EBITDA Multiple GNPX (Genprex)|Business Value to Operating Income Before Depreciation CLDI|Sunshine Biopharma - EV/EBITDA Multiple|XBIO - EV/EBITDA Multiple|Salarius Pharmaceuticals (SLRX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|purple-biotech.com - Business Value to Operating Income Before Depreciation|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio BeiGene Ltd. (BGNE)|EV/EBITDA Multiple CKPT|EV/EBITDA Multiple Elevation Oncology Inc. (ELEV)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iCAD ICAD|IKNA: Enterprise Value to Operating Income Before Depreciation|Notable Labs - EV/EBITDA Multiple|Viracta Therapeutics (VIRX) - Enterprise Value to EBITDA Ratio|MOR: EV/EBITDA Multiple|Company Value to EBITDA NAYA Biosciences Corp (NAYA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascentage Pharma Group
